dc.contributor |
Háskóli Íslands |
dc.contributor |
University of Iceland |
dc.contributor.author |
Schaller, Martin |
dc.contributor.author |
Sigurgeirsson, Bárður |
dc.contributor.author |
Sarkany, Marlis |
dc.date.accessioned |
2017-12-19T14:12:26Z |
dc.date.available |
2017-12-19T14:12:26Z |
dc.date.issued |
2017-09-19 |
dc.identifier.citation |
Schaller, M., Sigurgeirsson, B., & Sarkany, M. (2017). Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis. Mycoses, 60(12), 800-807. doi:10.1111/myc.12676 |
dc.identifier.issn |
0933-7407 |
dc.identifier.issn |
1439-0507 (eISSN) |
dc.identifier.uri |
https://hdl.handle.net/20.500.11815/483 |
dc.description.abstract |
Patient adherence is a key consideration in the choice of a topical regimen for the treatment of onychomycosis. The objective of this study was to investigate patient-reported outcomes (treatment utilisation, adherence and satisfaction) in onychomycosis treated with once-weekly amorolfine 5% nail lacquer versus once-daily ciclopirox 8% nail lacquer (Study A) or once-daily urea 40% ointment/bifonazole 1% cream combination regimen (Study B). Study A: Subjects received amorolfine and ciclopirox on opposite feet for 12 weeks. Study B: Subjects received amorolfine and urea/bifonazole on opposite feet for 6-7 weeks. Assessments included subject adherence as per label, treatment preference and questionnaire. Study A: More subjects adhered to amorolfine (85%) than to ciclopirox (60%) (P = .025). Overall, subjects were satisfied (95% vs 100%, respectively) and the treatments were balanced in terms of preference (50% vs 45%) at week 12. Study B: More subjects adhered to amorolfine dosage (81.8%) than to the dosage of the urea/bifonazole combination regimen (59.1%) (P = .096). At the end of study, 85.7% of subjects preferred amorolfine versus 14.3% for urea/bifonazole. Fewer subjects experienced local side effects with amorolfine (4.5%) compared to urea (27.3%) and bifonazole (15%). Amorolfine 5% nail lacquer offers a simple and convenient treatment option, which may result in improved patient adherence and consequently lead to improved efficacy and patient satisfaction. |
dc.description.sponsorship |
Galderma |
dc.format.extent |
800-807 |
dc.language.iso |
en |
dc.publisher |
Wiley-Blackwell |
dc.relation.ispartofseries |
Mycoses;60(12) |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.subject |
Onychomycosis |
dc.subject |
Patient adherence |
dc.subject |
Patient reported outcomes |
dc.subject |
Sveppasýkingar |
dc.subject |
Neglur |
dc.subject |
Sjúklingar |
dc.title |
Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis |
dc.type |
info:eu-repo/semantics/article |
dcterms.license |
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
dc.description.version |
Peer Reviewed |
dc.identifier.journal |
Mycoses |
dc.identifier.doi |
10.1111/myc.12676 |
dc.contributor.department |
Læknadeild (HÍ) |
dc.contributor.department |
Faculty of Medicine (UI) |
dc.contributor.school |
Heilbrigðisvísindasvið (HÍ) |
dc.contributor.school |
School of Health Sciences (UI) |